Coronary flow reserve and exercise capacity in hypertrophic cardiomyopathy.
The aim of this study was to evaluate the relation of coronary flow velocity (CFV) and coronary flow reserve (CFR) to exercise capacity in ten verapamil-treated patients with hypertrophic cardiomyopathy (HC). Using Doppler transesophageal echocardiography, we assessed diastolic CFV in the proximal left anterior descending coronary artery at baseline and after administering 0.56 mg/kg intravenous dipyridamole. The CFR was calculated as the post-dipyridamole/baseline diastolic CFV ratio. A maximal symptom-limited exercise treadmill test was performed according to a modified Bruce protocol and the exercise capacity was expressed as metabolic equivalents. The mean value for baseline diastolic CFV was 59 +/- 27 cm/s; this increased after dipyridamole to 134 +/- 57 cm/s. The CFR was 2.37 +/- 0.67. Baseline diastolic CFV correlated negatively with both exercise duration (r = -0.69; P < 0.05) and value for metabolic equivalents (r = -0.70; P < 0.05). CFR was weakly and non-significantly related to exercise duration (r = 0.40; P > 0.05) and to the value for metabolic equivalents (r = 0.32; P > 0.05). Shortening of exercise time and decreasing metabolic equivalents were correlated with increased baseline diastolic CFV. Dipyridamole-assessed CFR, was weakly related to parameters of exercise capacity.
Second Department of Cardiology, Collegium Medicum Jagiellonian University, Kraków, Poland.
P P
PP
Dimitrow
M
M
Krzanowski
W
W
Bodzoń
A
A
Szczeklik
J S
JS
Dubiel
D000328:Adult; D001783:Blood Flow Velocity; D002312:Cardiomyopathy, Hypertrophic / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D003326:Coronary Circulation / Q000187:drug effects; D004176:Dipyridamole / Q000008:administration & dosage; D017548:Echocardiography, Transesophageal; D017079:Exercise Tolerance / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D012680:Sensitivity and Specificity; D014665:Vasodilator Agents / Q000008:administration & dosage; D014700:Verapamil / Q000627:therapeutic use
D014665:Vasodilator Agents; D004176:Dipyridamole; D014700:Verapamil